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Abstract
Background: KCNQ channels have been widely studied in the nervous system, heart and inner
ear, where they have important physiological functions. Recent reports indicate that KCNQ
channels may also be expressed in portal vein where they are suggested to influence spontaneous
contractile activity. The biophysical properties of K+ currents mediated by KCNQ channels
resemble a current underlying the resting K+ conductance and resting potential of pulmonary artery
smooth muscle cells. We therefore investigated a possible role of KCNQ channels in regulating the
function of pulmonary arteries by determining the ability of the selective KCNQ channel blockers,
linopirdine and XE991, to promote pulmonary vasoconstriction.
Methods: The tension developed by rat and mouse intrapulmonary or mesenteric arteries was
measured using small vessel myography. Contractile responses to linopirdine and XE991 were
measured in intact and endothelium denuded vessels. Experiments were also carried out under
conditions that prevent the contractile effects of nerve released noradrenaline or ATP, or block
various Ca2+ influx pathways, in order to investigate the mechanisms underlying contraction.
Results: Linopirdine and XE991 both contracted rat and mouse pulmonary arteries but had little
effect on mesenteric arteries. In each case the maximum contraction was almost as large as the
response to 50 mM K+. Linopirdine had an EC50 of around 1 µM and XE991 was almost 10-fold
more potent. Neither removal of the endothelium nor exposure to phentolamine or α,β-
methylene ATP, to block α1-adrenoceptors or P2X receptors, respectively, affected the
contraction. Contraction was abolished in Ca2+-free solution and in the presence of 1 µM nifedipine
or 10 µM levcromakalim.
Conclusion: The KCNQ channel blockers are potent and powerful constrictors of pulmonary
arteries. This action may be selective for the pulmonary circulation as mesenteric arteries showed
little response. The results imply that the drugs act directly on smooth muscle cells and contraction
requires voltage-dependent Ca2+ influx. It is concluded that the drugs probably act by blocking
KCNQ channels in pulmonary artery myocytes, leading to membrane depolarization and Ca2+
influx through L-type Ca2+ channels. This implies a functional role for KCNQ channels in regulating
the resting membrane potential of pulmonary artery myocytes.
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Background
KCNQ (Kv7) genes encode a family of voltage-gated K+
channels with 6 membrane spanning domains and a sin-
gle P-loop that forms the selectivity filter of the pore.
Members of this channel family have been widely studied
in the nervous system, heart and inner ear, where they
have important physiological functions [1,2]. In the nerv-
ous system, KCNQ channels are thought to underlie the
M-current, a non-inactivating, voltage-dependent K+ cur-
rent that plays a critical role in regulating neuronal excita-
bility and action potential firing frequency [3]. It was
originally thought that M-current is mediated by heterom-
ultimeric channels formed by KCNQ2 and KCNQ3 subu-
nits [4], but it may also require association with the
regulatory, KCNE2 subunit [5]. Moreover, K+  currents
with characteristics similar to M-current can also be pro-
duced by homomultimers of KCNQ1, KCNQ2, KCNQ3,
KCNQ4 and KCNQ5 [2], as well as heteromers of KCNQ3
and KCNQ5 [6,7]. Thus there may be significant molecu-
lar diversity in the composition of M-like currents in dif-
ferent cell types.
K+ currents produced by the heterologous expression of
different KCNQ genes in Xenopus oocytes or mammlian
cell lines display distinct properties. In general though,
they can be activated at rather negative membrane poten-
tials, below -60 mV, are outwardly rectifying and show lit-
tle or no inactivation [2]. Similar characteristics are
displayed by a K+  current found in pulmonary artery
smooth muscle cells, which plays a key role in regulating
the resting membrane potential [8]. Although part of this
current has been proposed to be mediated by two-pore
domain TASK channels [9], there is a residual component
that remains to be identified. Its similarity to the M-cur-
rent has led us to speculate that it might be mediated by
KCNQ channels and that KCNQ channels might therefore
play a role in regulating the resting membrane potential of
pulmonary artery smooth muscle cells. Consistent with
this idea, expression of KCNQ1 and the regulatory subu-
nit, KCNE4, has been reported in lung [10,11]. Although
not examined in pulmonary arteries, KCNQ1 transcripts
have also been reported in the mouse portal vein [12],
where there is evidence that they have a functional role in
regulating spontaneous contractile activity [13].
Inhibition of the K+ channels contributing to the resting
membrane potential of pulmonary artery smooth muscle
cells would cause membrane depolarisation. If the cells
depolarise sufficiently to reach the threshold for activating
L-type Ca2+ channels, the result would be Ca2+ influx and
muscle contraction. The ability of inhibitors of KCNQ
channels to induce pulmonary artery contraction would
therefore provide support for a role of these channels in
regulating the resting potential. Due to their selective inhi-
bition of KCNQ channels, the drugs linopirdine and
XE991 (a more potent analogue of linopirdine) have been
used as markers of these channels [1,2]. Their effect on M-
current is thought to be a major factor in the abilities of
these drugs to stimulate the release of central neurotrans-
mitters [14], an action that led to these drugs being con-
sidered as cognition enhancers and investigated for the
treatment of Alzheimer's disease. Linopirdine inhibits
native M-currents at low micromolar concentrations and
is around 20-fold less potent at inhibiting other voltage-
gated K+ channels [15]. Linopirdine and XE991 inhibit
heterologously expressed KCNQ channels with varying
potency, depending on their subunit composition, but at
concentrations effective at blocking KCNQ channels they
are without effect on a number of other recombinant K+
channels [2,4,16].
This study investigated the effects of the KCNQ channel
blockers, linopirdine and XE991, on isolated rat and
mouse pulmonary arteries, with the aim of determining
whether or not KCNQ channels could potentially play a
role in regulating the resting membrane potential and
tone of pulmonary artery smooth muscle.
Methods
This investigation was carried out under regulations dic-
tated by the UK Scientific Procedures (Animals) Act 1986
and conforms to the Guide for the Care and Use of Labora-
tory Animals published by the National Institutes of
Health (NIH Publication No. 85-23, revised 1996). Male
Sprague Dawley rats (250–300 g) and BALB/c mice (4–5
weeks old) were killed by cervical dislocation. The lungs
and mesentery were rapidly excised into physiological salt
solution (PSS) containing (mM): NaCl 120; KCl 5; MgCl2
1; NaH2PO4 0.5; KH2PO4 0.5; glucose 10; CaCl2 1; pH
7.4. Intrapulmonary arteries and mesenteric arteries with
external diameters of 300–400 µm (rats) or 100–200 µm
(mice) were dissected free of connective tissue and
mounted in a small vessel myograph (Danish Myotech-
nology). The vessels were bathed in PSS, continually aer-
ated at 37°C. A basal tension of 5 mN (rat) or 4 mN
(mouse) was applied and vessels allowed to equilibrate
for 40 min, washing every 15 min, before beginning the
experiment.
At the start of each experiment, vessels were exposed to 50
mM K+ until a maximal contractile response was observed.
This was done by replacing the PSS in the bath with PSS
in which the K+ concentration was increased to 50 mM by
equimolar substitution of KCl for NaCl. The vessels were
then washed until tension returned to baseline and the
challenge with high K+ was repeated until reproducible
contractions were produced. Following washout and
recovery of tension to baseline, the tissue was then
exposed to increasing concentrations of linopirdine (1 nM
– 100 µM) or XE991 (0.1 nM – 100 µM), applied in aRespiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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cumulative manner with an interval of at least 10 min
between additions. Contractile responses to these drugs
were measured as a percentage of the response to 50 mM
K+ in each vessel. In some experiments the endothelium
was removed by rubbing the lumen of the vessel with a
human hair. The failure of acetylcholine (1 µM) to relax
vessels pre-constricted with 1 µM phenylephrine was
taken to indicate successful denudation. As relaxant
responses were not always abolished by this procedure,
experiments on endothelium-denuded vessels were also
carried out in the presence of the nitric oxide synthase
inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME,
100 µM) and the cyclooxygenase inhibitor indomethacin
(10 µM).
Rat intrapulmonary arteries were used to investigate the
mechanism of constriction caused by the KCNQ channel
blockers. The response to a single application of linopird-
ine (10 µM) or XE991 (1 µM) was first established. After
washout and recovery to baseline tension, the tissue was
then bathed for 20 min in Ca2+-free bath solution, which
was identical to PSS but with CaCl2 omitted and 1 mM
EGTA added. The vessels were then challenged again with
linopirdine or XE991. To control for time-dependent
changes in the response amplitude, in some experiments
linopirdine or XE991 was first applied in Ca2+-free bath
solution and the application repeated after returning to
normal PSS. The effects of nifedipine (1 µM), levcromaka-
lim (10 µM) and phentolamine (10 µM) on contractile
KCNQ channel blockers constrict pulmonary, but not mesenteric artery Figure 1
KCNQ channel blockers constrict pulmonary, but not mesenteric artery. Original records of tension developed by 
rat (A, B) and mouse (C, D) intrapulmonary artery (IPA) in the presence of 50 mM KCl or increasing concentrations of linopir-
dine or XE991, applied where indicated. Original records of tension developed by rat (E) and mouse (F) mesenteric arteries 
(MA) show responses to 50 mM KCl, but not linopirdine or XE991 applied at the same concentrations. Calibration bars are 1 
mN (vertical) and 10 min (horizontal).Respiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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responses to the KCNQ channel blockers were tested in a
similar way. Vessels were challenged once with linopird-
ine (10 µM) or XE991 (1 µM) under control conditions
and once in the presence of each of these drugs.
The dihydrochloride salts of linopirdine and XE991 were
purchased from Tocris Bioscience. Stock solutions (10
mM) prepared in distilled water were stored as frozen
aliquots and diluted to the final bath concentration in
PSS. A few experiments used linopirdine from Sigma,
stored as a 10 mM stock dissolved in dimethylsulphoxide.
Nifedipine, levcromakalim, phentolamine hydrochloride,
phenylephrine hydrochloride, acetylcholine chloride and
ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-
tetraacetic acid (EGTA) were all from Sigma. Data are
expressed as means ± S.E.M of n animals and compared
using paired or unpaired Student's t test, as appropriate.
Differences were considered statistically significant when
p < 0.05.
Results
Pulmonary vasoconstriction by KCNQ channel blockers
When applied to rat intrapulmonary arteries both linopir-
dine and XE991 produced concentration-dependent con-
traction with an amplitude that was often as large as the
contraction induced by 50 mM K+ (Fig 1A,B). Figure 2A
shows the concentration-response curve for linopirdine,
constructed from the mean data obtained from 6 vessels.
Concentration-response curves for pulmonary artery constriction by KCNQ channel blockers Figure 2
Concentration-response curves for pulmonary artery constriction by KCNQ channel blockers. Concentration 
dependence of contraction induced by linopirdine (A) or XE991 (B) in rat intrapulmonary arteries that were intact (+E) or 
denuded of endothelium (-E). Plots also show the mean responses of rat mesenteric arteries (MA) at the same drug concentra-
tions. Each point represents the mean ± SEM of 5–6 experiments. C. Concentration dependence of contraction induced by 
linopirdine (n = 9) or XE991 (n = 11) in intact mouse intrapulmonary arteries. Responses were measured in each vessel as a 
percentage of the contractile response to 50 mM KCl.Respiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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Each increase in drug concentration was made after con-
traction had appeared to reach a steady level and tension
was measured as the level reached immediately before
addition of the higher concentration. It can be seen that
the drug was maximally effective at 10 µM. When the data
in Fig 1A was pooled with experiments in which vessels
were challenged with a single application of 10 µM
linopirdine, the mean contraction at this concentration
had an amplitude 85 ± 12% (n = 21) of that induced by
50 mM K+. No further contraction was observed at higher
linopirdine concentrations. In fact, upon addition of 100
µM linopirdine, vessels displayed relaxation (Fig. 1A)
with tension returning around 30% towards the baseline
(Fig. 2A). This precluded fitting the Hill equation to
obtain the concentration producing 50% of the maxi-
mum response (EC50), which was instead estimated by
interpolation of the concentration-response curves for
each vessel tested. This gave EC50 = 1.3 ± 0.5 µM (n = 6)
for linopirdine. XE991 was more potent than linopirdine,
often producing substantial contractions below 10 nM
(Fig. 1B). The EC50, estimated as above, was 0.4 ± 0.3 µM
(n = 6). The maximal response was usually observed at 1
or 10 µM XE991, where it was nearly as large as the con-
tractile response to 50 mM K+ (Fig 2B). The mean ampli-
tude of all contractions induced by 1 µM XE991 was 79 ±
8% (n = 21) of the response to K+. This was not signifi-
cantly different from the maximum response to linopird-
ine. As seen with linopirdine, during cumulative
applications of XE991 relaxation was sometimes observed
at high concentrations (10 µM). The time course of the
contractile responses to linopirdine and XE991 were
somewhat variable. Most figures show traces in which the
contractions developed over 15 min or so and recovered
fully within around 30 min. In many tissues however,
Mechanism of contraction induced by KCNQ channel blockers Figure 4
Mechanism of contraction induced by KCNQ channel blockers. Original records show contractile responses of rat 
intrapulmonary artery to 50 mM KCl, followed by 10 µM linopirdine (A, C, E) or 1 µM XE991 (B, D, F) under control conditions 
and in the presence of Ca2+-free (0Ca) bathing solution (A, B), 1 µM nifedipine (C, D) or 10 µM levcromakalim (E, F).Respiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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contraction took up to 30 min to develop, sometimes
beginning after a substantial delay (e.g. Fig. 4D), and
complete recovery often took over an hour after washing.
This variable time course means that although, during
experiments, contraction appeared to reach a steady level
at each concentration, it may not always have developed
fully at low concentrations (e.g. Fig. 1A,B,D), which could
cause the EC50 values to be overestimated.
Both linopirdine and XE991 had similar effects on mouse
intrapulmonary arteries (Fig. 1C,D). The concentration
dependence of their actions on mouse vessels is shown in
Fig. 2C. The EC50 for linopirdine, estimated as above, was
0.6 ± 0.2 µM (n = 9). The EC50 for XE991 was 0.12 ± 0.03
µM (n = 11), making it significantly more potent than
linopirdine (p < 0.05). The drugs were maximally effective
at the same concentrations observed in rat arteries and the
maximal contractions of mouse pulmonary artery to the
two drugs were not significantly different. Linopirdine (10
µM) induced a contraction amounting to 54 ± 12% (n =
9) of the response to 50 mM K+ while the contraction
induced by 1 µM XE991 was 61 ± 10% (n = 11) of the
response to K+. Also as observed in rat, during cumulative
applications a relaxation response to both drugs became
Contraction is independent of nerve released noradrenaline or ATP Figure 3
Contraction is independent of nerve released noradrenaline or ATP. A. Original record showing contraction of rat 
intrapulmonary artery to 10 µM linopirdine before and then during exposure to 10 µM phentolamine. B. Original record show-
ing contraction of rat intrapulmonary artery to 10 µM linopirdine after exposing the tissue to 10 µM phentolamine plus 1 µM 
α,β-methylene ATP for 30 min and then again following washout of phentolamine and α,β-methylene ATP. Calibration bars are 
1 mN (vertical) and 10 min (horizontal). Drug applications are indicated. B. Histogram showing the mean amplitudes of con-
tractile responses to 10 µM linopirdine and 1 µM XE991 under control conditions (C) and following 30 min exposure to 10 
µM phentolamine (Phen) or Phen plus 1 µM α,β-methylene ATP (α,β-mATP). Responses were measured in each vessel as a 
percentage of the contractile response to 50 mM KCl. The number of observations is shown next to each bar.Respiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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apparent at the highest concentrations tested (Fig. 1C,D,
Fig. 2C.
In contrast to the effects of linopirdine and XE991 on pul-
monary arteries, neither drug had a significant effect on
mesenteric arteries from the same animals. Original traces
show little effect on rat (Fig. 1E) or mouse (Fig. 1F)
mesenteric arteries, despite them contracting strongly in
response to the application of 50 mM K+. The lack of effect
is clear in the concentration-effect curves shown for rat in
Fig. 2A,B, where responses in mesenteric artery are directly
compared with intrapulmonary arteries of similar size.
KCNQ channel blockers act directly on pulmonary artery 
smooth muscle
Both linopirdine and XE991 continued to constrict pul-
monary arteries after endothelial function was blocked, by
removing endothelium from the vessel lumen and inhib-
iting the release of nitric oxide and prostacyclin. In fact the
concentration-response curves to linopirdine (Fig. 2A)
and XE991 (Fig. 2B) were essentially unaltered in the
absence of endothelium, indicating that the presence of
endothelium is not needed for the drugs to cause contrac-
tion.
Linopirdine is known to evoke the release of neurotrans-
mitters by inhibiting neuronal K+ channels [14]. It is
therefore possible that KCNQ channel blockers constrict
pulmonary arteries by releasing neurotransmitters from
nerve terminals in the vessel wall, which in turn activate
the contractile response. The pulmonary circulation is
innervated by sympathetic nerves, which release
noradrenaline to activate contraction via α1-adrenocep-
tors located on the smooth muscle. To investigate the
potential involvement of noradrenaline in the response to
the KCNQ channel blockers, we determined the ability of
phentolamine, an α-adrenoceptor antagonist, to prevent
the constrictor response. As shown in Fig. 3, phen-
tolamine (10 µM), at a concentration more than sufficient
to inhibit the actions of nerve released noradrenaline, had
no significant effect on the contractions induced by 10 µM
linopirdine or 1 µM XE991. In rat small intrapulmonary
arteries the main transmitter evoking excitation and con-
traction is ATP, acting on P2 receptors [17]. We investi-
gated the potential role of this transmitter by blocking its
action with α,β-methylene ATP (1 µM), applied in the
presence of phentolamine (10 µM). At this concentration
α,β-methylene ATP depolarises the membrane and causes
contraction, followed by repolarisation and relaxation
Contraction requires voltage-dependent Ca2+ influx Figure 5
Contraction requires voltage-dependent Ca2+ influx. Histogram comparing the mean amplitudes of contractile 
responses to 10 µM linopirdine or 1 µM XE991 under control conditions and in the presence of Ca2+-free (0Ca) bathing solu-
tion (n = 6 for both drugs), 1 µM nifedipine (Nif; n = 5 for both drugs) or 10 µM levcromakalim (Lev; n = 4 for linopirdine; n = 
5 for XE991). Responses were measured in each vessel as a percentage of the contractile response to 50 mM KCl. ***p < 
0.001, **p < 0.01, *p < 0.05 compared with paired control.Respiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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over the next 15–30 min as P2X1 receptors become desen-
sitised [17,18]. At this time, vessels fail to respond to the
application of ATP [18]. Following 30 min exposure to 1
µM α,β-methylene ATP, linopirdine (10 µM) and XE991
(1 µM) continued to induce constriction of rat pulmonary
artery (Fig. 3C). The amplitudes of the contractions
induced by linopirdine and XE991 were not significantly
different when the drugs were applied under control con-
ditions or after 30 min exposure to α,β-methylene ATP
and phentolamine (Fig. 3D).
Pulmonary artery constriction requires voltage-dependent 
Ca2+ influx
To determine how much of the contraction induced by
KCNQ channel blockers required Ca2+ influx from the
extracellular space, we investigated the effect on the
response of removing extracellular Ca2+. When vessels
were exposed to Ca2+-free PSS for 20 min before applying
10 µM linopirdine (Fig. 4A) or 1 µM XE991 (Fig. 4B) the
drugs had essentially no effect on tension, although they
produced contraction in the same vessels exposed to nor-
mal PSS, whether applied before the test in Ca2+-free solu-
tion or after the normal Ca2+ concentration had been
restored. Fig. 5 summarises the mean results and shows
that in the absence of extracellular Ca2+ the contractile
responses to linopirdine and XE991 were essentially abol-
ished.
Several distinct pathways could potentially mediate Ca2+
influx underlying the contraction of pulmonary artery
smooth muscle. To determine the contribution of voltage-
gated, L-type Ca2+ channels, we investigated the effects of
the selective Ca2+ channel antagonist, nifedipine, on con-
tractions induced by the KCNQ channel blockers. When
nifedipine (1 µM) was applied to vessels pre-constricted
with 10 µM linopirdine (Fig. 4C) or 1 µM XE991 (Fig. 4D)
the tension rapidly declined to the baseline. In addition,
when vessels were pre-exposed to nifedipine (1 µM) for
10 min, linopirdine and XE991 failed to produce contrac-
tion (not shown). Comparison of the mean amplitudes of
contractions evoked by linopirdine or XE991 in the
absence and presence of nifedipine shows that nifedipine
essentially abolished the contractile responses to both
drugs (Fig. 5).
If the contractions induced by linopirdine and XE991
depend on membrane depolarisation and activation of
Ca2+  influx through voltage-gated Ca2+  channels, then
they should be inhibited under conditions that promote
hyperpolarisation and oppose the depolarising action of
the drugs. To determine if this was the case, we examined
how the contractions were affected by the K+ channel
opening drug, levcromakalim. This drug activates KATP
channels and causes hyperpolarisation of pulmonary
artery smooth muscle cells [19]. At 10 µM, levcromakalim
hyperpolarises pulmonary artery smooth muscle cells by
around 15 mV [20], taking the membrane potential well
away from the voltage threshold for activating L-type Ca2+
channels. When applied in the presence of 10 µM levcro-
makalim neither 10 µM linopirdine (Fig. 4E) nor 1 µM
XE991 (Fig. 4F) caused contraction in vessels that
responded well to both drugs after levcromakalim was
washed from the tissue with PSS for around 10 min. Com-
parison of the mean amplitudes of contractions evoked by
linopirdine or XE991 in the absence and presence of lev-
cromakalim shows that the contractile responses to both
drugs were essentially abolished (Fig. 5).
Discussion
The KCNQ channel blockers, linopirdine and XE991,
were both found to act as potent constrictors of rat and
mouse pulmonary arteries. Linopirdine constricted arter-
ies from both species with an EC50 of around 1 µM, which
is similar to the 2–3 µM concentrations found for 50%
inhibition (IC50) of native M current in hippocampal neu-
rons and sympathetic ganglia [15,21]. It is also close to
the IC50  values reported for inhibition of homomeric
KCNQ1 (8.9 µM), KCNQ2 (~4 µM) and KCNQ3 (4.8 µM)
channels and heteromeric KCNQ2/3 channels (3.5–10
µM) and at least 10-fold lower than reported for other
homomeric or heteromeric KCNQ channels [2]. XE991
generally has a 10-fold lower IC50 for KCNQ channels
than linopirdine, although the relative potency of the
drugs varies among different KCNQ subunits and subunit
combinations [2]. It blocks KCNQ1 and KCNQ2 homom-
ers, as well as KCNQ2/3 heteromers, with an IC50 of 0.6–
0.8 µM, which is similar to the EC50 estimated for pulmo-
nary artery constriction. Our EC50 measurements may
have been affected by the presence of a relaxant action at
the top end of the concentration-effect curve, leading to a
possible underestimate. Nevertheless, the potencies
found in this study are among the highest reported for
linopirdine or XE991 actions in any tissue, consistent with
the idea that they produced pulmonary vasoconstriction
through an interaction with KCNQ channels.
The pulmonary vasoconstrictor effects of linopirdine and
XE991 appear to be mediated by a direct action on the
smooth muscle cells of the vessel wall. They do not
require the presence of an intact endothelium, because
removing the endothelium did not alter the contractile
response to either drug. Since KCNQ channel blockers are
known to stimulate neurotransmitter release [14], it was
important to check the potential involvement of neuronal
KCNQ channels in the vasoconstrictor response, the
blockade of which might result in transmitters being
released from nerve endings in the artery wall. Neither
inhibition of α1-adrenoceptors with phentolamine, nor
desensitization of P2X receptors with α,β-methylene ATP,
had any effect on the pulmonary vasoconstrictorRespiratory Research 2006, 7:31 http://respiratory-research.com/content/7/1/31
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responses to linopirdine or XE99l. Since these are the
main transmitters mediating electrical and contractile
responses to nerve stimulation in rat intrapulmonary
arteries [17,22], it is highly unlikely that neurotransmit-
ters released in the vessel wall play a significant role in
mediating the pulmonary vasoconstrictor effect of the
KCNQ channel blockers.
The pulmonary vasoconstriction induced by linopirdine
or XE991 was abolished in Ca2+-free medium. This indi-
cates that the contraction was dependent upon Ca2+ influx
from the extracellular space into the smooth muscle cells
and did not involve Ca2+ release from intracellular stores.
Furthermore, abolition of the constrictor responses in the
presence of nifedipine indicates that Ca2+ entered the cells
through voltage-gated, L-type Ca2+ channels. This is what
would be expected if the KCNQ channel blockers were
producing constriction by blocking resting K+ channels
and inducing depolarisation of the smooth muscle cell
membrane. That this is the mechanism underlying the
vasoconstrictor responses to linopirdine and XE991 is fur-
ther supported by the ability of levcromakalim, a KATP
channel opener, to abolish the responses. At the concen-
tration used, levcromakalim hyperpolarizes pulmonary
artery smooth muscle cells close to the K+ equilibrium
potential [19,20]. This is demonstrated by its lack of effect
on the tension developed by vessels exposed to a high
extracellular K+ concentration [20,23], where vessels con-
tract due to membrane depolarization and Ca2+ influx.
The pronounced effect of levcromakalim on the responses
to linopirdine and XE991 contrasts with only partial inhi-
bition of the constrictor responses to a number of receptor
agonists, where it blocks only the component of contrac-
tion that results from voltage-dependent Ca2+  influx
[20,23]. This implies that the constrictor responses to
linopirdine and XE991 are strongly dependent on the
membrane potential and/or K+ flux, and voltage-gated
Ca2+ influx.
Linopirdine has generally been found to be well tolerated
in humans, with few adverse effects. Pulmonary vasocon-
striction is, however, a potentially serious side effect that
might not be picked up by routine examinations. Since
linopirdine and XE991 constricted pulmonary arteries
while having no effect on mesenteric arteries from the
same species, they are likely to elevate pulmonary arterial
pressure without a change in systemic blood pressure.
Consistent with this, linopirdine had no effect on blood
pressure or pulse rate in human volunteers [24]. Possible
effects on the pulmonary circulation have not been inves-
tigated in vivo. The lack of effect on mesenteric arteries sug-
gests that the vasoconstrictor action of KCNQ channel
blockers may be selective for the pulmonary circulation. A
recent report indicates that linopirdine (50 µM) and
XE991 (10 µM) can also modulate the spontaneous con-
tractions of portal vein [13], but these effects were
observed at higher concentrations than required to con-
strict pulmonary artery. Further studies are required to
determine if other blood vessels can be affected by these
drugs.
Conclusion
The KCNQ K+ channel blocking drugs, linopirdine and
XE991, are potent and powerful constrictors of pulmo-
nary arteries. This is a potentially serious side effect of the
drugs and should be considered as KCNQ blockers are
developed for clinical use. The lack of a similar response
in mesenteric arteries suggests that this action may be
selective for the pulmonary circulation. All of the data
point to an action on the smooth muscle cells of pulmo-
nary arteries, involving K+-channel blockade, membrane
depolarisation and Ca2+ influx as the mechanism underly-
ing the response. This strongly suggests that KCNQ chan-
nels play a functional role in pulmonary artery smooth
muscle, most likely contributing to the resting K+ conduct-
ance and resting potential. If so, then drugs like retigab-
ine, which activate KCNQ channels [2], could be effective
and selective dilators of pulmonary arteries and may
prove useful in the treatment of pulmonary hypertension.
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